Richard E Peschel MD, PhD
Professor Emeritus of Therapeutic Radiology
Intensity modulated radiation therapy; Prostate cancer; Prostate implant; Prostate specific antigen; Radiation therapy
Prostate cancer is now the most common malignancy diagnosed in American males and the second leading cause of cancer deaths. Although a variety of approaches (observation, surgery, external beam radiation therapy, brachytherapy, and hormone therapy) are available for prostate cancer, a review of the historical prostate cancer data provides little evidence that the most cost-effective and efficacious therapies are being utilized. The prostate specific antigen (PSA) has revolutionized our understanding of the proper diagnosis and treatment of prostate cancer.
The clinical research programs at the Hunter Radiation Therapy Center include programs to scientifically evaluate the efficacy of surgery versus various forms of radiation therapy including implant therapy, three-dimensional conformal external beam radiation therapy, and intensity modulated radiation therapy (IMRT) for treatment of early prostate cancer. IMRT represents the newest form of radiation therapy for prostate cancer. We are using IMRT with dose escalation for all of our prostate cancer patients. We have recently received a grant from the Anna Fuller Foundation to evaluate the clinical outcomes using IMRT and a new technology called image-guided IMRT.